Загрузка...
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treate...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3359733/ https://ncbi.nlm.nih.gov/pubmed/22371887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-405456 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|